The future of T cell manufacturing for immunotherapy - an interview with Dr. Ohad Karnieli

Dr. Ohad Karnieli, founder and CEO of ADVA Biotechnology, and his team have developed a modular cell expansion system, that enables autologous cell therapy manufacturing - at the bedside. The meaning of this is quite impactful: a shorter time period between the patient’s blood sampling and the beginning of the treatment, at a significantly lower price. The new technology is expected to enable this treatment to a much larger portion of patients in need.
In this interview, Dr. Karnieli explains the principles and main features of the ADVA X³ system - An autologous cell proliferation and expansion system.

[@donardnghadeh293]

Hi, I've been trying to contact the company. I haven't been able to. Would you advise how I can get a hold. I tried the number on the website from Isreal. Also, the "info" email address. Any guidance would greatly appreciated it.